Prostate cancer has a long disease history and a wide variety and uncertainty in individual
patients' clinical progress. In recent years, we have seen a revolutionary advance in both …

Despite advances in prostate cancer diagnosis and management, morbidity from prostate
cancer remains high. Approximately 20% of men present with advanced or metastatic …

Tumor expression of prostate-specific membrane antigen (PSMA) is lost in 15–20% of men
with castration-resistant prostate cancer (CRPC), yet the underlying mechanisms remain …

Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole …

Summary Enhancer of Zeste 2 (EZH2) is the enzymatic subunit of Polycomb Repressive
Complex 2 (PRC2), which catalyzes histone H3 lysine 27 trimethylation (H3K27me3) at …

Protein methyl transferases play critical roles in numerous regulatory pathways that underlie
cancer development, progression and therapy-response. Here we discuss the function of …

The prostate cancer (PCa) risk-associated SNP rs11672691 is positively associated with
aggressive disease at diagnosis. We showed that rs11672691 maps to the promoter of a …

Patients with cancer carry somatic sequence variants in their tumour in addition to the
germline variants in their inherited genome. Although variants in protein-coding regions …

Findings over the past decade have identified aberrant activation of the ETS transcription
factor family throughout all stages of tumorigenesis. Specifically in solid tumours, gene …

The analysis of exonic DNA from prostate cancers has identified recurrently mutated genes,
but the spectrum of genome-wide alterations has not been profiled extensively in this …